The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding the Good Manufacturing Practice (GMP) certification approval process being sought by the Company for its European Medicinal Cannabis Laboratory and Extraction Facility.
The Company requests that the trading halt end on the earlier of the commencement of normal trading on Thursday 25 January 2018, or when the announcement referred to above is released to the market.
Ann: Trading Halt, page-2
-
- There are more pages in this discussion • 195 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
